Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.37201/req/045.2021 http://scihub22266oqcxt.onion/10.37201/req/045.2021 33982984!8329576!33982984     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Esp+Quimioter 2021 ; 34 (4): 337-341 Nephropedia Template TP {{tp|p=33982984|t=2021. Experience with the use of siltuximab in patients with SARS-CoV-2 infection |pdf=|usr=}}{{33982984}} gab.com Text Experience with the use of siltuximab in patients with SARS-CoV-2 infection JO: Rev Esp Quimioter http://www.kidney.de/pget.php?&tw=1&pmid=33982984 #FOAvip OBJECTIVE: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. METHODS: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. RESULTS: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). CONCLUSIONS: Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein. Twit Text FOAVip Experience with the use of siltuximab in patients with SARS-CoV-2 infection ????Rev Esp Quimioter http://www.kidney.de/pget.php?&tw=1&pmid=33982984 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33982984 #FOAvip English Wikipedia <ref>{{Cite pmid|33982984}}</ref> Experience with the use of siltuximab in patients with SARS-CoV-2 infection #MMPMID33982984 Meira F; Albiach L; Carbonell C; Martin-Oterino JA; Martin-Ordiales M; Linares L; Macaya I; Aguero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; Garcia-Pouton N; Garcia-Vidal C; Gonzalez-Cordon A; Hernandez-Meneses M; Inciarte A; Laguno M; Leal L; Morata L; Puerta-Alcalde P; Rico V; Letona L; Cozar-Llisto A; Duenas G; Sola M; Torres B; Rojas J; Moreno A; Moreno-Garcia E; Torres M; Martinez JA; Soriano A; Garcia F Rev Esp Quimioter 2021[Aug]; 34 (4): 337-341 PMID33982984show ga OBJECTIVE: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammatory flare. METHODS: Retrospective review of the first 31 patients with SARS-CoV-2 treated with siltuximab, in Hospital Clinic of Barcelona or Hospital Universitario Salamanca, from March to April 2020 with positive polymerase-chain reaction (PCR) from a nasopharyngeal swab. RESULTS: The cohort included 31 cases that received siltuximab with a median (IQR) age of 62 (56-71) and 71% were males. The most frequent comorbidity was hypertension (48%). The median dose of siltuximab was 800 mg ranging between 785 and 900 mg. 7 patients received siltuximab as a salvage therapy after one dose of tocilizumab. At the end of the study, a total of 26 (83.9) patients had been discharged alive and the mortality rate was 16.1% but only 1 out of 24 that received siltuximab as a first line option (4%). CONCLUSIONS: Siltuximab is a well-tolerated alternative to tocilizumab when administered as a first line option in patients with COVID-19 pneumonia within the first 10 days from symptoms onset and high C-reactive protein. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antibodies, Monoclonal/*therapeutic use[MESH] |C-Reactive Protein/analysis[MESH] |COVID-19/mortality[MESH] |Cytokine Release Syndrome/drug therapy/etiology[MESH] |Disease Progression[MESH] |Female[MESH] |Humans[MESH] |Hypertension/complications[MESH] |Interleukin-6/antagonists & inhibitors/blood[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Salvage Therapy[MESH]Experience with the use of siltuximab in patients with SARS-CoV-2 infe(epmc).pdf DeepDyve Pubget Overpricing